{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-086933","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2026-08-10T11:00:41+00:00","discovered_at":"2026-08-10T11:05:00.366873+00:00","generated_at":"2026-08-10T11:05:59.784790+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oruka Q2 net loss $41.2M; EVERLAST-A 63.5% PASI 100; cash $1.1B","bullets":["Q2 2026 net loss $41.2M vs $24.6M in Q2 2025; R&D spend $43.3M; cash $1.1B funds through BLA filing.","EVERLAST-A Phase 2a: 40/63 (63.5%) achieved PASI 100 at Week 16; PASI 90 83%; IGA 0/1 84%.","EVERLAST-B fully enrolled (187 subjects); Week 16 data expected Q4 2026; Phase 3 for ORKA-001 in 1H 2027.","ORCA-SPLASH Phase 2 in HS initiated (~160 patients); ORKA-004 TL1A antibody enters clinic Q4 2026.","May 2026: IL-23 license with Paragon amended to include all therapeutic areas incl. IBD."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-086933","json":"https://secwatch.observer/filing/0001213900-26-086933.json","markdown":"https://secwatch.observer/filing/0001213900-26-086933.md","text":"https://secwatch.observer/filing/0001213900-26-086933.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000121390026086933/0001213900-26-086933-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000121390026086933/ea0301312-8k_oruka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T11:05:59.784790+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}